Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of ITI-214 in Patients With Heart Failure

Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of Escalating Single Doses of ITI-214 in Patients With Systolic Heart Failure

This is a Phase I/II randomized, double-blind, placebo-controlled, single rising dose study in patients with systolic heart failure to evaluate the safety and tolerability of ITI-214.

Inclusion Criteria:

• NYHA class II-III heart failure
• Ejection fraction equal to or below 35%
• On stable heart failure drug treatment

Exclusion Criteria:

• Considered medically inappropriate for study participation